Published on September 22, 2009 at 5:33 AM
NicOx S.A. (NYSE Euronext Paris: COX) today announced that an important scientific article has been published in the September issue of the American Journal of Cardiology. The publication describes the blood pressure results from the 301 phase 3 study for naproxcinod in detail. Naproxcinod is the first-in-class Cyclooxygenase-Inhibiting Nitric Oxide Donating (CINOD) anti-inflammatory agent for the relief of the signs and symptoms of osteoarthritis (OA). The submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for naproxcinod is planned later this month and the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) is planned in Q4.
The objective of these analyses was to assess the impact of naproxcinod 750 mg bid, naproxcinod 375 mg bid, placebo and naproxen 500 mg bid, a widely used non-selective traditional non-steroidal anti-inflammatory drug (NSAID), on the systolic blood pressure (SBP) of patients with OA of the knee.
SOURCE: NICOX